68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer

Tumor, Solid Clinical Trial

Official title: Clinical Applications of Fibroblast Activation Protein Inhibitor-Based Dimeric Radiotracer 68Ga-DOTA-F2 PET/CT Imaging for Malignant Tumors

Status Recruiting

Clinical Trial Summary

To evaluate the potential usefulness of 68Ga-DOTA-F2 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer, compared with 18F-FDG PET/CT.

Clinical Trial Description

Quinoline-based fibroblast activation protein (FAP) inhibitors (FAPIs; e.g., FAPI-04 and FAPI-46), which have shown promising results in the diagnosis of cancer and various other diseases in recent years, have become the focus of much productive research. Despite this, one major issue is that these FAPI molecules have a relatively short tumor retention time, which may limit their use in targeted radionuclide therapy applications. As a result, 68Ga-DOTA-F2, a novel dimeric FAPI molecule, was developed to increase tracer uptake and retention in tumors for potential therapeutic or theranostic applications. In preclinical study, 68Ga-DOTA-F2 has shown better tumor uptake and longer tumor retention time than 68Ga-FAPI in mouse tumor models. Our study will assess image quality and evaluate the diagnostic performance of 68Ga-DOTA-F2. Patients with histologically confirmed malignant tumors will be prospectively recruited in this study. ;

Related Conditions & MeSH terms

• Tumor, Solid

• NCT number: NCT05637034
• Study type: Interventional
• Source: Peking Union Medical College Hospital
• Contact: Peipei Wang, MD
• Phone: 18511395988
• Email: wpp199411@163.com
• Status: Recruiting
• Phase: N/A
• Start date: September 15, 2022
• Completion date: September 15, 2023